English

   Home      Contact

NEWS ARCHIVE

Fakta-fakta Baru dalam Pengobatan Lupus Nefritis
› Fakta-fakta tentang Protokol JD
Remisi Artritis Reumatoid dengan Terapi Milenium
  (Kompas, Minggu, 19 Mei 2002)

  Download
Lupus, Penyakit Seratus Wajah (Kompas, Minggu, 21 Juli 2002)
  Download

 
NOVEMBER 2005
16.11.2005 MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis
SEPTEMBER 2005
06.09.2005 Roche files first rheumatoid arthritis indication for MabThera in Europe
APRIL 2005
06.04.2005 MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies
NOVEMBER 2004
02.11.2004 Positive Outcome Confirms Efficacy of MabThera in Moderate-Severe Rheumatoid Arthritis
AUGUST 2004
23.08.2004 New perspectives in the fight against autoimmunity
APRIL 2004
22.04.2004 CellCept's cardioprotective profile reinforced
OCTOBER 2003
27.10.2003 Long-term data shows MabThera to be a highly promising treatment for Rheumatoid Arthritis (RA)
DECEMBER 2001
06.12.2001 Roche renews support for Roche Organ Transplantation Research Foundation for a further three years

 

 


 


 

  Email This Page   Print This Page

 
NEWS & EVENTS

LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

16.11.2005
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis


Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart

more

 

 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.09.2005
Roche files first rheumatoid arthritis indication for MabThera in Europe

MabThera: a medicine used to treat non-Hodgkin's lymphoma


MabThera delivers significant and sustained relief from symptoms in patients with difficult-to-treat rheumatoid arthritis.
more

 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.04.2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies

Third large randomised trial to evaluate efficacy and safety of MabThera in RA

Roche, Genentech and Biogen Idec announced today that REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its primary endpoint in the group of patients with the most difficult-to-treat rheumatoid arthritis (RA).

more

Legal Disclamer

Legal Disclaimer

Copyright ©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases.

This Web site was developed in 2005 as a service provided by the WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases. This Web site provides selected information available about lupus and arthritis. It is important that public see a healthcare professional for detailed information about medical conditions and treatment. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. The WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases has made and will continue to make efforts to include accurate and up-to-date information on this Web site.

If you have any questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
 


Supported by PT Roche Indonesia